GlassScriptPhysician profile
Priscilla Yeon
NPI 1861965790
$20,393.75
in general payments reported to CMS, 2019-2025
33 companies · $5,906 in 2025
The $5,906 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,532 · 2022: $2,948 · 2023: $4,169 · 2024: $4,839 · 2025: $5,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $1,188 · Education: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,116.20 |
| Consulting Fee | $1,188.00 |
| Education | $609.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,280.64 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $2,109.25 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,960.31 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,493.72 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Dermavant Sciences, INC. | $1,310.04 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $1,234.52 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Incyte Corporation | $1,116.56 | 2021-2025 | Opzelura |
| Genzyme Corporation | $1,061.52 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,040.14 | 2022-2025 | Sotyktu |
| Ucb, INC. | $922.83 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $874.79 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Lilly USA, LLC | $832.60 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Leo Pharma INC. | $494.31 | 2021-2024 | Adbry |
| Pfizer INC. | $434.07 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $396.61 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $391.82 | 2021-2025 | Klisyri |
| Vyne Pharmaceuticals INC. | $309.73 | 2021 | |
| Journey Medical Corporation | $300.55 | 2022-2023 | |
| Arcutis Biotherapeutics, INC. | $255.41 | 2023-2025 | Zoryve |
| Organon LLC | $253.13 | 2024-2025 | Vtama |
| Botanix Sb INC | $234.46 | 2025 | Sofdra |
| Janssen Scientific Affairs, LLC | $198.94 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $154.53 | 2022-2025 | Clindacin Etz |
| Amgen INC. | $140.19 | 2022-2025 | Otezla, Otezla |
| Allergan, INC. | $125.00 | 2022 | |
| Boston Scientific Corporation | $120.85 | 2022-2023 | Varithena Administration Pack |
| Revance Therapeutics, INC. | $115.18 | 2024 | Daxxify |
| Epi Health, LLC | $86.75 | 2021-2022 | |
| Biofrontera INC. | $40.71 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.43 | 2022 | |
| Kyowa Kirin, INC. | $28.66 | 2022 | |
| Smith+Nephew, INC. | $27.24 | 2021 | |
| Merz North America, INC. | $16.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priscilla Yeon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.